Edwards Lifesciences
1,193 hedge funds and large institutions have $31.9B invested in Edwards Lifesciences in 2024 Q3 according to their latest regulatory filings, with 140 funds opening new positions, 370 increasing their positions, 499 reducing their positions, and 227 closing their positions.
147% more call options, than puts
Call options by funds: $733M | Put options by funds: $296M
1.85% less ownership
Funds ownership: 81.93% → 80.08% (-1.9%)
8% less funds holding
Funds holding: 1,295 → 1,193 (-102)
26% less repeat investments, than reductions
Existing positions increased: 370 | Existing positions reduced: 499
30% less capital invested
Capital invested by funds: $45.6B → $31.9B (-$13.7B)
38% less first-time investments, than exits
New positions opened: 140 | Existing positions closed: 227
60% less funds holding in top 10
Funds holding in top 10: 15 → 6 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.06B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$655M |
| 3 |
Ninety One (UK)
London,
United Kingdom
|
+$501M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$266M |
| 5 |
BlackRock
New York
|
+$262M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$971M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
-$652M |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$487M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$419M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$303M |
EW Hedge Fund Activity: Q3 2024 in Review
1,193 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2024, worth a combined $31.9B — down 30% from $45.6B a quarter earlier.
Sellers outnumbered buyers: 227 funds closed out of EW and 140 opened new positions — a net loss of 87 holders — while 499 trimmed existing stakes and 370 added.
The largest buyer was Wellington Management Group, adding an estimated $1.06B. The largest seller was AllianceBernstein, cutting an estimated $971M.
- 1,193 institutional investors held Edwards Lifesciences (EW) as of Q3 2024, down from 1,295 in Q2 2024.
- Funds reported $31.9B of Edwards Lifesciences stock for Q3 2024, down 30% quarter-over-quarter.
- 140 funds opened new Edwards Lifesciences positions in Q3 2024 and 227 closed out, a net change of -87 holders.
- The largest Edwards Lifesciences buyer in Q3 2024 was Wellington Management Group, an estimated $1.06B added.
- The largest Edwards Lifesciences seller in Q3 2024 was AllianceBernstein, an estimated $971M sold.
Based on aggregated 13F filings for Q3 2024.